Immuno Cure may file for HK listing in H2 after pre-IPO round

Immuno Cure may file for HK listing in H2 after pre-IPO round

30 March, 2026

Edited by: Padma Priya

Chapter 18A clinical-stage biotech hong kong ICVAX Immuno Cure IPO

Printed by Unregistered user on Mon, 30 Mar 2026 03:04:43 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

KKR leads additional investment in Chinese fungal biotech firm Sylvan

Chinese biotech firm Zenitar files for HK IPO after $86m Series C financing

Read more from Greater China

Earnings and Results

BYD’s annual profit drops for first time in four years as price war hurts margins

How ByteDance pulled ahead of rivals in China’s AI race